Trial Profile

A phase 2b study of IMC-2 (Celecoxib+valacyclovir-Virios-Therapeutics) for long covid

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2024 According to Virios Therapeutics media release, Virios Therapeutics has changed its name to Dogwood Therapeutics.
21 May 2024 New trial record
17 May 2024 According to Virios Therapeutics media release, company today announced that it intends to offer and sell up to $2.1 million in shares of its common stock in a public offering and intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com